Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

Corrigendum to "Lynch syndrome-associated epithelial ovarian cancer and its immunological profile" [Gynecologic Oncology 162 (2021) 686-693]

Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review


  1. Vaginal melanoma in Denmark from 1980 to 2018: A population-based study based on genetic profile and survival

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Assessment of recurrence rate and risk factors of relapse in stage in IA vulvar carcinoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Endometriosis and menopausal hormone therapy impact the hysterectomy-ovarian cancer association

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Real-world data on melanoma brain metastases and survival outcome

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. B Cells and Tertiary Lymphoid Structures: Friends or Foes in Cancer Immunotherapy?

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Drop in cancer diagnosis during the COVID-19 pandemic in Denmark: assessment of impact during 2020

    Publikation: Bidrag til tidsskriftLetterForskningpeer review

Vis graf over relationer

The authors regret that there were some errors in their article. Please see below for further details. In the results, section 2.2, it should be Spearman's correlation coefficient and not Pearson's. Just as stated in the method section. In the method section: The authors wrote: “All women with verified pathogenic germline variants in the MMR genes MLH1, MSH2, MSH6 and PMS2 and their first-degree relatives diagnosed with ovarian cancer between January 1st, 1980 to September 24th, 2019 were identified through the Danish Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Register (N=83).” It should be N = 82 instead since one of them was bilateral. In the discussion, the authors have made two small calculation/rounding errors: They wrote: “When focusing on MMR-d tumors, 61–85% of these are MSI-H for endometrial cancers and 39% for ovarian cancer [40–42].Our ovarian cancer data add to this observation with an agreement between the two assays of only 56%.” It should be 38% and not 39%. And 58% instead of 56%. The authors would like to apologise for any inconvenience caused.

TidsskriftGynecologic Oncology
Udgave nummer1
Sider (fra-til)242
Antal sider1
StatusUdgivet - jan. 2022

ID: 69274885